1. The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn's disease (CD) 
S. Malik, S.F. Ahmed, M.L. Wilson, N. Shah, S. Loganathan, S. Naik, B. Bourke, A. Thomas, A.K. Akobeng, A. Fagbemi, D.C. Wilson, R.K. Russell 
Journal of Crohn's and Colitis 
Volume 6, Issue 3, Pages (April 2012)
DOI: /j.crohns
Copyright © Terms and Conditions

2. Figure 1
PCDAI values in children with CD at baseline (T0) and in the 6months (T+6) and 12months (T+12) following start of adalimumab therapy. a — PCDAI in overall of 19 children at baseline (T0) and 6months following adalimumab therapy; b — PCDAI in overall group of 12 children at baseline (T0) and 6months (T0) and 12months (T+12) following adalimumab therapy. (■) and (■) indicate remission and no-remission.
Journal of Crohn's and Colitis 2012 6, DOI: ( /j.crohns )
Copyright © Terms and Conditions

3. Figure 2
Growth in children with CD during the 6months prior to adalimumab therapy (T0) and in the 6months following start of therapy (T+6); a — change in height standard deviation scores (ΔHtSDS) in overall group of 36 children; b — change in height standard deviation scores (ΔHtSDS) in overall group of 28 children who had remission after adalimumab therapy; c — height velocity (HV, cm/year) in overall group of 28 children who had remission — box and whisker plots represent median, 10th, 25th, 75th, and 90th centiles.
Journal of Crohn's and Colitis 2012 6, DOI: ( /j.crohns )
Copyright © Terms and Conditions

4. Figure 3
The relationship between change in height standard deviation scores over the 6months before (ΔHtSDS0, x-axis) and the 6months after (ΔHtSDS+6, y-axis) starting adalimumab therapy in children with CD. The children in quadrant a — had slow growth before starting adalimumab therapy but had improved growth after treatment. The children in quadrant b — had normal growth both before and after adalimumab therapy. The children in quadrant c — had normal growth before but had slow growth after starting adalimumab therapy. The children in quadrant d — had slow growth before and after starting adalimumab therapy. (■) and (o) indicate remission and no-remission.
Journal of Crohn's and Colitis 2012 6, DOI: ( /j.crohns )
Copyright © Terms and Conditions

5. Figure 4
Growth response based upon the indication for using adalimumab therapy as (i) allergic reaction to infliximab (ii) loss-of-response to infliximab and (iii) primary nonresponder to infliximab. a — Change in height standard deviation scores (ΔHtSDS) in 11 children who had an allergic reaction. b — Change in height standard deviation scores (ΔHtSDS) in 16 children who had a loss of response. c — Change in height standard deviation scores (ΔHtSDS) in 7 children who were primary nonresponders.
Journal of Crohn's and Colitis 2012 6, DOI: ( /j.crohns )
Copyright © Terms and Conditions

6. Figure 5
a. Growth in children with CD during the 6months prior to adalimumab therapy (T0) and in the 6months following start of therapy (T+6). (i) — Change in height standard deviation scores (ΔHtSDS) in 17 children who were at Tanner stages I–III at starting adalimumab. (ii) — Change in height standard deviation scores (ΔHtSDS) in 10 children who were at Tanner stages IV–V pubertal at starting adalimumab.
b. Growth in children who were on prednisolone therapy at starting adalimumab; (i) — change in height standard deviation scores (ΔHtSDS) in 15 children who had received prednisolone therapy when starting adalimumab. (ii) — Change in height standard deviation scores (ΔHtSDS) in 21 children who did not receive prednisolone therapy when starting adalimumab.
c. Growth in children who were on immunosuppression therapy when starting adalimumab; (i) — Change in height standard deviation scores (ΔHtSDS) in 23 children who had received immunosuppression therapy on starting adalimumab. (ii) — Change in height standard deviation scores (ΔHtSDS) in 13 children who did not had receive immunosuppression therapy when starting adalimumab. All box...Box and whisker plots represent median, 10th, 25th, 75th, and 90th centiles.
Journal of Crohn's and Colitis 2012 6, DOI: ( /j.crohns )
Copyright © Terms and Conditions